Sun Pharma and Cipla seen as having more upside
Systematix analyst Vishal Manchanda said Sun Pharmaceutical Industries and Cipla offer relatively better upside among large-cap pharma stocks. He added that increasing licensing deals with Chinese drugmakers could help lower oncology drug prices in India.